Phospho-M-CSF Receptor (Tyr699) Antibody

• 产品编号：CST-3399S      品牌：CST       原厂货号：3399S
• 产品分类：抗体 > 一抗 > 磷酸化抗体
• 应用分类：

描述：

磷酸化M-CSF 受体(Tyr699)的抗体仅在M-CSF 受体的Tyr699位点磷酸化时能检测到内源M-CSF 受体蛋白的表达。本抗体与其它激活的酪氨酸激酶，包括PDGF受体，发生微弱的交叉反应。多克隆抗体通过用多肽免疫动物得到，该磷酸化多肽是根据人的M-CSF 受体蛋白Tyr699附近的氨基酸序列合成的。抗体经过protein A和亲和层析纯化。巨噬细胞集落刺激因子（M-CSF, CSF-1）受体是由原癌基因c-fms编码的一种膜嵌合的酪氨酸激酶。M-CSF 受体表达在单核细胞（巨噬细胞及其前体细胞）上并促进这一系列血细胞的生长和发育(1-3)。M-CSF和它的受体结合后会引起受体二聚化、激活、以及细胞质内作为含SH2信号蛋白结合位点的酪氨酸残基自磷酸化(4)。至少有5个主要的酪氨酸自磷酸化位点。Tyr723 (小鼠Tyr721)位于激酶插入（KI）区。磷酸化的Tyr723能够与PI3K激酶的p85亚基以及PLC-γ 2结合(5)。磷酸化的Tyr809能够为Shc提供停泊位点（5）。该受体的过度激活会导致各种细胞体系呈现出恶性特征（6）。激活的M-CSF 受体表明晚期上皮样卵巢癌（7）和乳腺癌预后不良（8）。M-CSF 受体的Tyr669位点磷酸化是Cell Signaling Technology (CST)公司利用LC-MS/MS平台PhosphoScan®技术和质谱检测技术在寻找磷酸化位点过程中发现的( 10)。M-CSF 受体的Tyr669位点是激酶插入区，它的自磷酸化能够为Grb2接头蛋白提供结合位点 (9)。

1. Stanley, E.R. et al. (1978) Nature 274, 168-70.
2. Byrne, P.V. et al. (1981) J Cell Biol 91, 848-53.
3. Bourette, R.P. and Rohrschneider, L.R. (2000) Growth Factors 17, 155-66.
4. Novak, U. et al. (1996) Oncogene 13, 2607-13.
5. Bourette, R.P. et al. (1997) EMBO J 16, 5880-93.
6. Morley, G.M. et al. (1999) Oncogene 18, 3076-84.
7. Toy, E.P. et al. (2001) Gynecol Oncol 80, 194-200.
8. Maher, M.G. et al. (1998) Clin Cancer Res 4, 1851-6.
9. Hamilton, J.A. (1997) J. Leukoc. Biol. 62, 145-155.
10. Downing, J.R. et al. (1991) Mol Cell Biol 11, 2489-95.

原厂资料：

Specificity / Sensitivity

Phospho-M-CSF Receptor (Tyr699) Antibody detects endogenous levels of M-CSF receptor only when phosphorylated at Tyr699. The antibody may cross-react slightly with other activated tyrosine kinases including PDGF receptors.

、Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues around Tyr699 of human M-CSF receptor. Antibodies are purified by protein A and peptide affinity chromatography.

Background

Macrophage-colony stimulating factor (M-CSF, CSF-1) receptor is an integral membrane tyrosine kinase encoded by the c-fms proto-oncogene. M-CSF receptor is expressed in monocytes (macrophages and their progenitors) and drives growth and development of this blood cell lineage. (1-3). Binding of M-CSF to its receptor induces receptor dimerization, activation and autophosphorylation of cytoplasmic tyrosine residues used as docking sites for SH2-containing signaling proteins (4). There are at least five major tyrosine autophosphorylation sites. Tyr723 (Tyr721 in mouse) is located in the kinase insert (KI) region. Phosphorylated Tyr723 binds the p85 subunit of PI3 kinase as well as PLC-γ 2 (5). Phosphorylation of Tyr809 provides a docking site for Shc (5). Overactivation of this receptor can lead to a malignant phenotype in various cell systems (6). The activated M-CSF receptor has been shown to be a predictor of poor outcome in advanced epithelial ovarian carcinoma (7) and breast cancer (8).

Phosphorylation of M-CSF receptor on Tyr669 was identified at Cell Signaling Technology (CST) using PhosphoScan®, CST's LC-MS/MS platform for phosphorylation site discovery, as well as in another publication (10). Autophosphorylation at Tyr699 in the kinase insert (KI) domain appears to provide a binding site for the Grb2 adaptor protein (9).

1. Stanley, E.R. et al. (1978) Nature 274, 168-70.
2. Byrne, P.V. et al. (1981) J Cell Biol 91, 848-53.
3. Bourette, R.P. and Rohrschneider, L.R. (2000) Growth Factors 17, 155-66.
4. Novak, U. et al. (1996) Oncogene 13, 2607-13.
5. Bourette, R.P. et al. (1997) EMBO J 16, 5880-93.
6. Morley, G.M. et al. (1999) Oncogene 18, 3076-84.
7. Toy, E.P. et al. (2001) Gynecol Oncol 80, 194-200.
8. Maher, M.G. et al. (1998) Clin Cancer Res 4, 1851-6.
9. Hamilton, J.A. (1997) J. Leukoc. Biol. 62, 145-155.
10. Downing, J.R. et al. (1991) Mol Cell Biol 11, 2489-95.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.